215 related articles for article (PubMed ID: 18267032)
1. ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study.
Huang MY; Fang WY; Lee SC; Cheng TL; Wang JY; Lin SR
BMC Cancer; 2008 Feb; 8():50. PubMed ID: 18267032
[TBL] [Abstract][Full Text] [Related]
2. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
[TBL] [Abstract][Full Text] [Related]
3. Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population.
Gan Y; Li XR; Chen DJ; Wu JH
Asian Pac J Cancer Prev; 2012; 13(11):5721-4. PubMed ID: 23317245
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
[TBL] [Abstract][Full Text] [Related]
6. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
Lu X; Xiao S; Jin C; van der Straaten T; Li X
J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
[TBL] [Abstract][Full Text] [Related]
8. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population.
Li HY; Ge X; Huang GM; Li KY; Zhao JQ; Yu XM; Bi WS; Wang YL
Asian Pac J Cancer Prev; 2012; 13(7):3465-9. PubMed ID: 22994779
[TBL] [Abstract][Full Text] [Related]
9. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Braun MS; Richman SD; Thompson L; Daly CL; Meade AM; Adlard JW; Allan JM; Parmar MK; Quirke P; Seymour MT
J Clin Oncol; 2009 Nov; 27(33):5519-28. PubMed ID: 19858398
[TBL] [Abstract][Full Text] [Related]
10. Contribution of DNA Repair Xeroderma Pigmentosum Group D Genotypes to Colorectal Cancer Risk in Taiwan.
Chang WS; Yueh TC; Tsai CW; Ji HX; Wu CN; Wang SC; Lai YL; Hsu SW; Hsieh MH; Hsiao CL; Hung YW; Shih TC; Bau DT
Anticancer Res; 2016 Apr; 36(4):1657-63. PubMed ID: 27069143
[TBL] [Abstract][Full Text] [Related]
11. Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
Hardi H; Melki R; Boughaleb Z; El Harroudi T; Aissaoui S; Boukhatem N
BMC Cancer; 2018 Mar; 18(1):292. PubMed ID: 29544444
[TBL] [Abstract][Full Text] [Related]
12. Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan.
Huang MY; Wang YH; Chen FM; Lee SC; Fang WY; Cheng TL; Hou MF; Wang JY; Lin SR
Ann Surg Oncol; 2008 Mar; 15(3):872-80. PubMed ID: 18095031
[TBL] [Abstract][Full Text] [Related]
13. DNA repair genes polymorphisms and risk of colorectal cancer in Saudi patients.
Karam RA; Al Jiffry BO; Al Saeed M; Abd El Rahman TM; Hatem M; Amer MG
Arab J Gastroenterol; 2016 Sep; 17(3):117-120. PubMed ID: 27686263
[TBL] [Abstract][Full Text] [Related]
14. A haplotype encompassing the variant allele of DNA repair gene polymorphism ERCC2/XPD Lys751Gln but not the variant allele of Asp312Asn is associated with risk of lung cancer in a northeastern Chinese population.
Yin J; Vogel U; Ma Y; Qi R; Sun Z; Wang H
Cancer Genet Cytogenet; 2007 May; 175(1):47-51. PubMed ID: 17498557
[TBL] [Abstract][Full Text] [Related]
15. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
Hitre E; Budai B; Adleff V; Czeglédi F; Horváth Z; Gyergyay F; Lövey J; Kovács T; Orosz Z; Láng I; Kásler M; Kralovánszky J
Pharmacogenet Genomics; 2005 Oct; 15(10):723-30. PubMed ID: 16141798
[TBL] [Abstract][Full Text] [Related]
16. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome.
Le Morvan V; Smith D; Laurand A; Brouste V; Bellott R; Soubeyran I; Mathoulin-Pelissier S; Robert J
Pharmacogenomics; 2007 Dec; 8(12):1693-703. PubMed ID: 18085999
[TBL] [Abstract][Full Text] [Related]
17. Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy.
Zawiah M; Yousef AM; Kadi T; Yousef M; Majdalawi K; Al-Yacoub S; Al-Hiary R; Tantawi D; Mukred R; Ajaj AR
Drug Metab Pers Ther; 2018 Dec; 33(4):201-205. PubMed ID: 30207288
[TBL] [Abstract][Full Text] [Related]
18. Single nucleotide polymorphisms (SNPs) of ERCC2, hOGG1, and XRCC1 DNA repair genes and the risk of triple-negative breast cancer in Polish women.
Smolarz B; Makowska M; Samulak D; Michalska MM; Mojs E; Wilczak M; Romanowicz H
Tumour Biol; 2014 Apr; 35(4):3495-502. PubMed ID: 24402573
[TBL] [Abstract][Full Text] [Related]
19. Correlations of ICAM-1 gene polymorphisms with susceptibility and multidrug resistance in colorectal cancer in a Chinese population.
Liu LB; Liu T; Xin FZ
Medicine (Baltimore); 2017 Aug; 96(33):e7481. PubMed ID: 28816939
[TBL] [Abstract][Full Text] [Related]
20. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
Lamas MJ; Duran G; Balboa E; Bernardez B; Touris M; Vidal Y; Gallardo E; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2011 Mar; 12(3):433-42. PubMed ID: 21449681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
